{"id":"cab-oral-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reaction"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cabotegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the host genome, thereby suppressing HIV replication. The oral tablet formulation allows for convenient dosing in treatment-naive and treatment-experienced patients.","oneSentence":"CAB (cabotegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:07.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals)"},{"name":"HIV-1 infection in treatment-experienced adults with integrase inhibitor resistance (in combination with other antiretrovirals)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT05726019","phase":"PHASE2","title":"Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2022-02-05","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Coronary Artery Bypass","enrollment":100},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":"Coronary Artery Bypass Graft","enrollment":90},{"nctId":"NCT07348133","phase":"PHASE1","title":"Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2025-12-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT07267260","phase":"PHASE2","title":"Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-16","conditions":"Cirrhoses, Liver","enrollment":154},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT04131556","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants","status":"TERMINATED","sponsor":"Shire","startDate":"2019-10-25","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT06979388","phase":"PHASE1","title":"A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT04493684","phase":"PHASE1","title":"GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":91},{"nctId":"NCT07031128","phase":"PHASE4","title":"Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-06-11","conditions":"CABG","enrollment":250},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04844424","phase":"PHASE1","title":"A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":115},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT05392530","phase":"PHASE1","title":"A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-05-25","conditions":"Healthy","enrollment":23},{"nctId":"NCT04388501","phase":"PHASE1","title":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2021-06-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT05236231","phase":"PHASE1","title":"A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2022-02-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT04448964","phase":"PHASE1","title":"A Study of JNJ-70033093 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT06656676","phase":"NA","title":"WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-01-29","conditions":"HIV Prevention","enrollment":75},{"nctId":"NCT05578846","phase":"PHASE1","title":"Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-10-13","conditions":"Healthy Adult Participants","enrollment":42},{"nctId":"NCT03010059","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-02-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02405858","phase":"PHASE4","title":"A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-04-10","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":51},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04090086","phase":"PHASE1","title":"A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-16","conditions":"Healthy","enrollment":16},{"nctId":"NCT04310995","phase":"PHASE4","title":"Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-06-02","conditions":"Coronary Artery Bypass Graft, Radial Artery Grafts, Antispastic Therapy","enrollment":150},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06397508","phase":"PHASE1","title":"Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants","status":"COMPLETED","sponsor":"Agomab Spain S.L.","startDate":"2024-04-02","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06332638","phase":"PHASE1","title":"PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"HK inno.N Corporation","startDate":"2024-03-19","conditions":"Healthy","enrollment":36},{"nctId":"NCT04857892","phase":"PHASE1","title":"A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-04-21","conditions":"HIV Infections","enrollment":41},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT01896505","phase":"PHASE1","title":"A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2013-07-30","conditions":"Sarcoma","enrollment":54},{"nctId":"NCT05723510","phase":"PHASE1","title":"PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2023-03-06","conditions":"Healthy","enrollment":87},{"nctId":"NCT06164834","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-12-05","conditions":"Healthy","enrollment":48},{"nctId":"NCT04484337","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":138},{"nctId":"NCT03908593","phase":"PHASE4","title":"Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-10-14","conditions":"Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy, Coronary Artery Bypass","enrollment":232},{"nctId":"NCT05319912","phase":"PHASE1","title":"A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2014-04-07","conditions":"Healthy","enrollment":18},{"nctId":"NCT05528198","phase":"NA","title":"Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2018-12-28","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT05353010","phase":"PHASE1","title":"A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2022-05-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT05300555","phase":"PHASE4","title":"Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":50},{"nctId":"NCT04991571","phase":"PHASE1","title":"Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-29","conditions":"Chronic Kidney Disease","enrollment":27},{"nctId":"NCT04568772","phase":"PHASE1","title":"Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-11-25","conditions":"Gastroesophageal Reflux Disease","enrollment":19},{"nctId":"NCT04757974","phase":"PHASE1","title":"Low-dose Fostemsavir Extended Release Relative Bioavailability Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-03-05","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02346578","phase":"PHASE2","title":"Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.","status":"COMPLETED","sponsor":"Taro Iguchi, MD, PHD","startDate":"2014-12","conditions":"Castration-resistant Prostate Cancer","enrollment":104},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT03939273","phase":"NA","title":"The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart Surgery","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03","conditions":"Systemic Inflammatory Response Syndrome, Postoperative Shock, Coronary Artery Disease","enrollment":80},{"nctId":"NCT04686669","phase":"PHASE1","title":"A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations","status":"COMPLETED","sponsor":"Forendo Pharma Ltd","startDate":"2020-12-10","conditions":"Relative Bioavailability","enrollment":12},{"nctId":"NCT04221321","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT04231136","phase":"PHASE1","title":"Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-14","conditions":"Healthy","enrollment":19},{"nctId":"NCT04639804","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-06-06","conditions":"Healthy","enrollment":60},{"nctId":"NCT02853435","phase":"PHASE1","title":"To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-04","conditions":"Infections, Bacterial","enrollment":48},{"nctId":"NCT03149848","phase":"PHASE1","title":"Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":15},{"nctId":"NCT01220167","phase":"PHASE1","title":"Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water","status":"COMPLETED","sponsor":"Aquestive Therapeutics","startDate":"2008-08","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19},{"nctId":"NCT04171687","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-10-21","conditions":"Healthy","enrollment":36},{"nctId":"NCT03258515","phase":"PHASE1","title":"A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-06","conditions":"Solid Tumors","enrollment":45},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT03441984","phase":"PHASE1","title":"To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-02-26","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT01560780","phase":"PHASE3","title":"Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-02-01","conditions":"Coronary Artery Bypass","enrollment":84},{"nctId":"NCT03814642","phase":"PHASE1","title":"Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-21","conditions":"Healthy","enrollment":25},{"nctId":"NCT03985410","phase":"PHASE1","title":"Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers","status":"COMPLETED","sponsor":"Entasis Therapeutics","startDate":"2019-05-23","conditions":"Acinetobacter Baumannii-calcoaceticus Complex Infections","enrollment":32},{"nctId":"NCT04066257","phase":"PHASE1","title":"Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT03863938","phase":"PHASE1","title":"Food-Effect on PK and PD of Single Oral Dose of Tegoprazan in Healthy Male Subjects","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-03-27","conditions":"Healthy","enrollment":12},{"nctId":"NCT02201771","phase":"PHASE4","title":"Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2014-07","conditions":"Coronary Artery Bypass, Antiplatelet Agents","enrollment":500},{"nctId":"NCT02769065","phase":"PHASE1","title":"Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-05-05","conditions":"Alzheimer Disease, Healthy Volunteers","enrollment":179},{"nctId":"NCT03038009","phase":"PHASE4","title":"Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2018-10","conditions":"Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract, Proton Pump Inhibitor","enrollment":""},{"nctId":"NCT02184585","phase":"PHASE1","title":"Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-10","conditions":"Prostatic Hyperplasia","enrollment":84},{"nctId":"NCT02254447","phase":"PHASE1","title":"Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-02","conditions":"Cardiovascular Disease","enrollment":18},{"nctId":"NCT03237988","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Corvus Pharmaceuticals, Inc.","startDate":"2017-07-20","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT00246740","phase":"PHASE2","title":"Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2005-10","conditions":"Coronary Artery Bypass Grafting, Cardiopulmonary Bypass, Reperfusion Injury","enrollment":56},{"nctId":"NCT03138356","phase":"PHASE1","title":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":126},{"nctId":"NCT02040480","phase":"PHASE1","title":"Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-05","conditions":"Cancer","enrollment":18},{"nctId":"NCT01047449","phase":"NA","title":"Improving the Results of Heart Bypass Surgery Using New Approaches to Surgery and Medication","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2011-07","conditions":"Coronary Artery Disease","enrollment":250},{"nctId":"NCT02385071","phase":"PHASE1","title":"A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-04-28","conditions":"Healthy","enrollment":48},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT00536679","phase":"PHASE1","title":"Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-20","conditions":"Depressive Disorder and Anxiety Disorders","enrollment":16},{"nctId":"NCT01416363","phase":"PHASE1","title":"Healthy Volunteer Study Using 3 Different Formulations of Firategrast","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-20","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":38},{"nctId":"NCT02322671","phase":"PHASE1","title":"Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-23","conditions":"Respiratory Disorders","enrollment":18},{"nctId":"NCT02201316","phase":"PHASE1","title":"A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-03","conditions":"Gastritis","enrollment":18},{"nctId":"NCT02355561","phase":"PHASE1","title":"A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT02738931","phase":"PHASE1","title":"Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT02480439","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT02230046","phase":"PHASE1","title":"Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10","conditions":"Healthy","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAB Oral Tablets","genericName":"CAB Oral Tablets","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAB (cabotegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA. Used for HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals), HIV-1 infection in treatment-experienced adults with integrase inhibitor resistance (in combination with other antiretrovirals).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}